TLR4 and aneurysm: Moreover, rosiglitazone also plays a potential protective role in the formation and rupture of aneurysms through the inhibitory effect on c-Jun N-terminal kinase (JNK) phosphorylation and toll-like receptor 4 (TLR4) expression at the site of lesion formation (68).